Fibroblast growth factor 23 (fgf-23) concentrations in cats with early nonazotemic chronic kidney disease (ckd) and in healthy geriatric cats

Journal of Veterinary Internal Medicine

Volumn 27, Issue 2, 2013, Pages 227-233

  Finch, N C ^a   Geddes, R F ^a   Syme, H M ^a   Elliott, J ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Azotemia; Feline; GFR; Renal secondary hyperparathyroidism

Indexed keywords

CREATININE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CAT; CAT DISEASE; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS FILTRATION RATE; LONGITUDINAL STUDY; METABOLISM; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; UREMIA;

ANIMALS; AZOTEMIA; CAT DISEASES; CATS; CREATININE; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; LONGITUDINAL STUDIES; PARATHYROID HORMONE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; STATISTICS, NONPARAMETRIC;

ANIMALIA; FELIDAE;

EID: 84875256223     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/jvim.12036     Document Type: Article

References (47)

1. Isakova T, Gutierrez OM, Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 2009;76:705-716.
2. Nakai K, Komaba H, Fukagawa M. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol 2010;23:619-625.
3. Bielesz B. Emerging role of a phosphatonin in mineral homeostasis and its derangements. Eur J Clin Invest 2006;36(Suppl. 2):34-42.
4. Kumata C, Mizobuchi M, Ogata H, et al. Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am J Nephrol 2010;31:230-238.
5. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007;20:302-308.
6. Silver J, Naveh-Many T. FGF23 and the parathyroid glands. Pediatr Nephrol (Berlin, Germany) 2010;25:2241-2245.
7. Krajisnik T, Olauson H, Mirza MA, et al. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 2010;78:1024-1032.
8. Marsell R, Grundberg E, Krajisnik T, et al. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. Eur J Endocrinol 2008;158:125-129.
9. Bacchetta J, Dubourg L, Harambat J, et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 2010;95:1741-1748.
10. Kazama JJ, Gejyo F, Shigematsu T, et al. Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism. Ther Apher Dial 2005;9:328-330.
11. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003-4008.
12. Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007;195:125-131.
13. Cozzolino M, Mazzaferro S. The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease. Curr Vasc Pharmacol 2010;8:404-411.
14. Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010;77:292-298.
15. Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009;114:S34-S42.
16. Lavi-Moshayoff V, Wasserman G, Meir T, et al. PTH increases FGF23 gene expression and mediates the high FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010;299:F882-F889.
17. Finch NC, Syme HM, Elliott J. Parathyroid hormone concentration in geriatric cats with various degrees of renal function. J Am Vet Med Assoc 2012;241:1326-1335.
18. Barber PJ, Elliott J. Feline chronic renal failure: Calcium homeostasis in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract 1998;39:108-116.
19. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002;87:4957-4960.
20. Geddes RF, Finch NC, Elliot J, et al. Fibroblast growth factor 23 in feline chronic kidney disease. J Vet Intern Med 2013; DOI: 10.1111/jvim.12044.
21. Finch NC, Syme HM, Elliott J, et al. Glomerular filtration rate estimation by use of a correction formula for slope-intercept plasma iohexol clearance in cats. Am J Vet Res 2011;72:1652-1659.
22. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005;90:1519-1524.
23. Hasegawa H, Nagano N, Urakawa I, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010;78:975-980.
24. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007;18:2600-2608.
25. Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005;67:1171-1178.
26. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-1378.
27. Pitts TO, Piraino BH, Mitro R, et al. Hyperparathyroidism and 1, 25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988;67:876-881.
28. Llach F, Velasquez Forero F. Secondary hyperparathyroidism in chronic renal failure: Pathogenic and clinical aspects. Am J Kidney Dis 2001;38:S20-S33.
29. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-38.
30. Schiavi SC, Kumar R. The phosphatonin pathway: New insights in phosphate homeostasis. Kidney Int 2004;65:1-14.
31. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-2215.
32. Takemoto F, Shinki T, Yokoyama K, et al. Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats. Kidney Int 2003;64:414-420.
33. Ix JH, Shlipak MG, Wassel CL, et al. Fibroblast growth factor-23 and early decrements in kidney function: The Heart and Soul Study. Nephrol Dial Transplant 2010;25:993-997.
34. Evenepoel P, Meijers B, Viaene L, et al. Fibroblast growth factor-23 in early chronic kidney disease: Additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010;5:1268-1276.
35. Razzaque MS. Phosphate toxicity: New insights into an old problem. Clin Sci (Lond) 2011;120:91-97.
36. Stubbs JR, Quarles LD. Fibroblast growth factor 23: Uremic toxin or innocent bystander in chronic kidney disease? Nephrol News Issues 2009;23:33-34, 36-37.
37. Nakatani T, Sarraj B, Ohnishi M, et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J 2009;23:433-441.
38. Galitzer H, Ben-Dov IZ, Silver J, et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010;77:211-218.
39. Canalejo R, Canalejo A, Martinez-Moreno JM, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010;21:1125-1135.
40. Filler G, Liu D, Huang SH, et al. Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease. Clin Biochem 2011;44:435-437.
41. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-2279.
42. Burnett SM, Gunawardene SC, Bringhurst FR, et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006;21:1187-1196.
43. Ito N, Fukumoto S, Takeuchi Y, et al. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 2007;25:419-422.
44. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-592.
45. Boyd LM, Langston C, Thompson K, et al. Survival in cats with naturally occurring chronic kidney disease (2000-2002). J Vet Int Med/Am Coll Vet Int Med 2008;22:1111-1117.
46. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010;5:286-291.
47. Elliott J, Rawlings JM, Markwell PJ, et al. Survival of cats with naturally occurring chronic renal failure: Effect of dietary management. J Small Anim Pract 2000;41:235-242.